These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35464416)

  • 41. Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
    Incorvaia L; Fanale D; Badalamenti G; Barraco N; Bono M; Corsini LR; Galvano A; Gristina V; Listì A; Vieni S; Gori S; Bazan V; Russo A
    Adv Ther; 2019 Oct; 36(10):2600-2617. PubMed ID: 31432460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
    Seol HY; Kim YS; Kim SJ
    Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Towards a survival risk prediction model for metastatic NSCLC patients on durvalumab using whole-lung CT radiomics.
    Patwardhan KA; RaviPrakash H; Nikolaou N; Gonzalez-García I; Salazar JD; Metcalfe P; Reischl J
    Front Immunol; 2024; 15():1383644. PubMed ID: 38915397
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab ± ipilimumab.
    Baxi V; Lee G; Duan C; Pandya D; Cohen DN; Edwards R; Chang H; Li J; Elliott H; Pokkalla H; Glass B; Agrawal N; Lahiri A; Wang D; Khosla A; Wapinski I; Beck A; Montalto M
    Mod Pathol; 2022 Nov; 35(11):1529-1539. PubMed ID: 35840720
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Deep learning-based image analysis predicts PD-L1 status from
    Liang C; Zheng M; Zou H; Han Y; Zhan Y; Xing Y; Liu C; Zuo C; Zou J
    Front Oncol; 2024; 14():1402994. PubMed ID: 39301549
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nonlinear association between PD-L1 expression levels and the risk of postoperative recurrence in non-small cell lung cancer.
    Kojima K; Samejima H; Iguchi T; Tokunaga T; Okishio K; Yoon H
    Sci Rep; 2024 Jul; 14(1):15369. PubMed ID: 38965343
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study.
    Jiang Z; Dong Y; Yang L; Lv Y; Dong S; Yuan S; Li D; Liu L
    J Digit Imaging; 2021 Oct; 34(5):1073-1085. PubMed ID: 34327623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
    Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CT Image-Based Radiomic Analysis for Detecting PD-L1 Expression Status in Bladder Cancer Patients.
    Cao Y; Zhu H; Li Z; Liu C; Ye J
    Acad Radiol; 2024 Sep; 31(9):3678-3687. PubMed ID: 38556431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radiogenomic System for Non-Invasive Identification of Multiple Actionable Mutations and PD-L1 Expression in Non-Small Cell Lung Cancer Based on CT Images.
    Shao J; Ma J; Zhang S; Li J; Dai H; Liang S; Yu Y; Li W; Wang C
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230746
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A computed tomography-based radiomics signature for predicting expression of programmed death ligand 1 in head and neck squamous cell carcinoma.
    Zheng YM; Yuan MG; Zhou RQ; Hou F; Zhan JF; Liu ND; Hao DP; Dong C
    Eur Radiol; 2022 Aug; 32(8):5362-5370. PubMed ID: 35298679
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hybrid deep multi-task learning radiomics approach for predicting EGFR mutation status of non-small cell lung cancer in CT images.
    Gong J; Fu F; Ma X; Wang T; Ma X; You C; Zhang Y; Peng W; Chen H; Gu Y
    Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37972417
    [No Abstract]   [Full Text] [Related]  

  • 57. Pembrolizumab monotherapy for non-small cell lung cancer (NSCLC): can patient stratification be improved in the UK Tayside population? A retrospective cohort study.
    Mander ES; Merrick CB; Nicholson HA; Lord HK; Ferguson MJ; Smith G
    BMJ Open; 2023 Nov; 13(11):e076715. PubMed ID: 37989364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
    Li B; Qin W; Yang L; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
    J Transl Med; 2024 Feb; 22(1):195. PubMed ID: 38388379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
    Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
    Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    Nagasaki Y; Taki T; Nomura K; Tane K; Miyoshi T; Samejima J; Aokage K; Ohtani-Kim SJ; Kojima M; Sakashita S; Sakamoto N; Ishikawa S; Suzuki K; Tsuboi M; Ishii G
    J Natl Cancer Inst; 2024 Jul; 116(7):1158-1168. PubMed ID: 38459590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.